Cambium Bio Ltd
CMB
Company Profile
Business description
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
Contact
Unit 2.06, 31 Lexington Drive
Bella VistaNSW2153
AUST: +61 1300995098
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,844.60 | 35.70 | 0.41% |
| CAC 40 | 8,203.43 | 4.14 | 0.05% |
| DAX 40 | 24,433.06 | 183.16 | -0.74% |
| Dow JONES (US) | 50,872.11 | 86.10 | 0.17% |
| FTSE 100 | 10,227.33 | 145.87 | -1.41% |
| HKSE | 24,395.66 | 170.24 | -0.69% |
| NASDAQ | 25,678.82 | 250.84 | -0.97% |
| Nikkei 225 | 64,676.85 | 739.78 | -1.13% |
| NZX 50 Index | 13,129.49 | 74.59 | -0.56% |
| S&P 500 | 7,386.65 | 19.08 | -0.26% |
| S&P/ASX 200 | 8,634.40 | 43.00 | 0.50% |
| SSE Composite Index | 4,004.62 | 5.41 | -0.14% |